Goldman Sachs’s Anavex Life Sciences AVXL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$2.71M Sell
293,780
-117,879
-29% -$1.09M ﹤0.01% 3222
2025
Q1
$3.53M Sell
411,659
-126,882
-24% -$1.09M ﹤0.01% 2978
2024
Q4
$5.78M Sell
538,541
-123,561
-19% -$1.33M ﹤0.01% 2746
2024
Q3
$3.76M Buy
662,102
+204,939
+45% +$1.16M ﹤0.01% 2958
2024
Q2
$1.93M Sell
457,163
-77,049
-14% -$325K ﹤0.01% 3213
2024
Q1
$2.72M Buy
534,212
+267,639
+100% +$1.36M ﹤0.01% 3004
2023
Q4
$2.48M Buy
266,573
+45,556
+21% +$424K ﹤0.01% 3077
2023
Q3
$1.45M Sell
221,017
-99,183
-31% -$650K ﹤0.01% 3295
2023
Q2
$2.6M Sell
320,200
-351,612
-52% -$2.86M ﹤0.01% 3036
2023
Q1
$5.76M Sell
671,812
-31,093
-4% -$266K ﹤0.01% 2422
2022
Q4
$6.51M Buy
702,905
+393,592
+127% +$3.64M ﹤0.01% 2436
2022
Q3
$3.19M Sell
309,313
-48,547
-14% -$501K ﹤0.01% 3000
2022
Q2
$3.58M Sell
357,860
-80,904
-18% -$810K ﹤0.01% 2960
2022
Q1
$5.4M Buy
438,764
+58,299
+15% +$718K ﹤0.01% 2739
2021
Q4
$6.6M Buy
380,465
+272,791
+253% +$4.73M ﹤0.01% 2586
2021
Q3
$1.93M Buy
107,674
+17,557
+19% +$315K ﹤0.01% 3516
2021
Q2
$2.06M Sell
90,117
-45,755
-34% -$1.05M ﹤0.01% 3485
2021
Q1
$2.03M Buy
135,872
+101,457
+295% +$1.52M ﹤0.01% 3358
2020
Q4
$186K Buy
34,415
+10,317
+43% +$55.8K ﹤0.01% 4293
2020
Q3
$110K Buy
24,098
+2,611
+12% +$11.9K ﹤0.01% 4210
2020
Q2
$106K Sell
21,487
-19,889
-48% -$98.1K ﹤0.01% 4165
2020
Q1
$130K Buy
+41,376
New +$130K ﹤0.01% 4104
2018
Q4
Sell
-115,954
Closed -$317K 4077
2018
Q3
$317K Sell
115,954
-202,317
-64% -$553K ﹤0.01% 3645
2018
Q2
$833K Buy
318,271
+283,145
+806% +$741K ﹤0.01% 3292
2018
Q1
$97K Buy
+35,126
New +$97K ﹤0.01% 4022
2017
Q1
Sell
-10,384
Closed -$41K 4399
2016
Q4
$41K Sell
10,384
-7,543
-42% -$29.8K ﹤0.01% 4255
2016
Q3
$65K Sell
17,927
-5,124
-22% -$18.6K ﹤0.01% 4261
2016
Q2
$141K Sell
23,051
-32,889
-59% -$201K ﹤0.01% 4004
2016
Q1
$274K Buy
+55,940
New +$274K ﹤0.01% 3600